US FDA panel recommends agency authorize Merck's COVID-19 drug | Inquirer News

US FDA panel recommends agency authorize Merck’s COVID-19 drug

/ 06:20 AM December 01, 2021

Merck COVID-19 pill

FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS

BENGALURU — A panel of expert advisers to the U.S. Food and Drug Administration on Tuesday narrowly voted to recommend the agency authorize Merck & Co’s antiviral pill to treat COVID-19.

The U.S. drugmaker published data last week suggesting that the drug was significantly less effective than previously thought, reducing hospitalizations and deaths in its clinical trial of high-risk individuals by around 30%.


Still, medicines like Merck’s molnupiravir, developed with Ridgeback Biotherapeutics, are likely to become important therapeutic tools that people will be able to take at home as soon as COVID-19 symptoms arise.


A rival drug being developed by Pfizer Inc, called Paxlovid, is particularly promising, having shown an 89% reduction in hospitalizations and deaths in its clinical trial. The FDA could consider that drug within the next few months.

The FDA’s Antimicrobial Drugs Advisory Committee voted 13-10 to recommend the agency authorize the drug after discussing concerns that the drug could cause the virus to mutate as well as safety concerns about the potential for birth defects. Both FDA staff scientists and Merck have suggested the drug should not be recommended during pregnancy.

The vote comes as fears about the new Omicron variant have rattled financial markets and sparked concerns about the strength of the global economic recovery as the world continues to fight the coronavirus pandemic.

The oral therapies target parts of the virus that are not changed by mutations in the Omicron variant. They could become even more vital if vaccine-induced and natural immunity are threatened by the variant.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, FDA, Merck

© Copyright 1997-2024 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.